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Tobacco use is the leading cause of preventable mortality worldwide (1) . Over one-half of all persistent smokers will eventually die of a tobacco-related disease (1) .
The primary addictive substance in tobacco is nicotine. Cigarette smoking facilitates the rapid absorption of nicotine via pulmonary circulation into the brain within seconds. Nicotine binds to α4β2 nicotinic acetylcholine receptors (nAChRs) and causes the release of dopamine, norepinephrine, glutamate, serotonin, beta-endorphins, and other neurotransmitters. These nicotinic receptors are pentameric in nature and are made up of α and β subunits. The α subunit occurs in nine different isoforms (α2-α10), while the β subunit occurs in three different isoforms (β2-β4). Nicotinic receptors containing the α4 and β2 subunits (α4β2*nAChRs) are the most prevalent in the brain and are thought to play the largest role in nicotine's reinforcing effects (2) . Repeated exposure to nicotine causes upregulation of α4β2 nicotinic acetylcholine receptors, leading to an increase in their numbers, which subsequently reinforces the addiction (3). Although debate regarding the mechanism of upregulation continues to exist, proposed mechanisms include conformation changes of low-affinity receptors to highaffinity states, as well as decreased cell surface receptor degradation secondary to nicotine exposure (4) .
The reinforcing effects of nicotine are primarily tied to its stimulatory effect on the mesoaccumbens dopamine pathway, which consists of dopamine projects from the ventral tegmental area (VTA) to the nucleus accumbens (NAcc). Nicotine's action at α4β2*nAChRs in the VTA is thought to be the primary role behind nicotine's reinforcing effects; however, other subtypes, such as α6*nAChRs heavily located in the VTA and NAcc, are important as well. The α7*nAChRs are also important, as they are thought to play a role in regulating nicotine intake (25) . Tobacco dependence also has a genetic component. Two single-nucleotide polymorphisms in CHRNA4 (the gene coding for the α4 subunit of nAChRs) are biologically functional and associated with tobacco dependence phenotypes (5) .
Pharmacotherapies are effective treatments for tobacco dependence and are recommended by the United States Public Health Service to be provided in conjunction with behavioral therapy (6) ( Tables 1 and 2 ). Nicotine replacement therapy, such as the nicotine patch, acts mainly at the α4β2*nAChRs, while buproprion is an antagonist at nAChRs. Varenicline is a partial agonist at α4β2*nAChRs, as well as a full agonist at α7*nAChRs (2) . The present article focuses primarily on first-line pharmacotherapies for tobacco dependence (7).
NICOTINE REPLACEMENT THERAPY
All nicotine replacement therapy products are recommended as first-line agents to treat tobacco dependence (6, 7) (Table 1) . Nicotine replacement therapies deliver nicotine via oral or nasal mucosa, thus reducing the severity of withdrawal symptoms and cravings associated with tobacco use cessation (6, 7) . A Cochrane meta-analysis of 150 trials demonstrated that nicotine replacement therapy increases long-term smoking abstinence compared with placebo or controls without nicotine replacement therapy (relative risk=1.60; 95% confidence interval [CI]=1.53-1.68) (7).
Nicotine Gum
Nicotine gum is available over the counter in 2-mg or 4-mg dose forms and increases smoking abstinence rates at 12 months compared with a control intervention (relative risk=1.43; 95% CI=1.31-1.56; 32 studies) (7) . As monotherapy, standard dosing for highly dependent smokers is 4 mg, as this dose showed higher abstinence rates compared with the 2-mg dose (4, 5) . Nicotine gum side effects include hiccups, gastrointestinal upset, and jaw discomfort associated with chewing (7).
Nicotine Lozenges
Nicotine lozenges are available over the counter in 2-mg or 4-mg dose forms, and a meta-analysis demonstrated their efficacy in increasing abstinence rates at 6 months compared with placebo (relative risk=1.90; 95% CI=1.36-2.67; four trials) (7) . Lozenges provide at liberty dosing in response to cravings and release 25% more nicotine than an equal dose of gum. The lozenge is placed in the buccal cavity, allowing for nicotine absorption through the oral mucosa. It may be preferable to gum for patients with oral problems (8) .
Nicotine Patches
Nicotine patches are available over the counter in various formulations and dosing schedules (i.e., 15 mg/16 hours; 7 mg, 14 mg, and 21 mg/24 hours). The nicotine patch is neither designed to alleviate acute cravings nor replace the behavioral activities of smoking in comparison to other types of nicotine replacement therapy (6) . Nicotine patches provide slow, transdermal nicotine delivery over 16-24 hours and have been shown to significantly increase sustained 12-month abstinence rates (relative risk=1.51; 95% CI=1.35-1.70; 21 trials), with the most common side effect being mild skin irritation at the application site (7) . Highest dose should be started in individuals smoking 10 or more cigarettes per day (3). In a preference trial comparing nicotine replacement therapy products, smokers preferred nicotine patches the most (8).
Nasal Sprays
Nasal sprays are available through prescription and deliver nicotine through nasal mucosa. One spray through each nostril constitutes a dose. Patients can initially use 1 or 2 doses/hour but should not exceed 5 doses/hour or 40 doses/day (9) . Nasal sprays deliver nicotine faster than gum, patches, or inhalers but less rapidly than cigarettes (9) . Nasal sprays increase smoking abstinence at 6 months greater than placebo (relative risk=2.02; 95% CI=1.49-2.73; four trials) (7). Side effects include rhinorrhea and nasal irritation (7).
Nicotine Inhalers
Nicotine inhalers require a prescription and deliver nicotine into the oropharynx where it is absorbed across the buccal mucosa (7) . It addresses the sensory and ritualistic aspects of smoking behavior (10) . Nicotine inhalers increase longterm abstinence compared with placebo (relative risk=1.90; 95% CI=1.36-2.67; four trials) (11) . The most common side effects reported are oropharyngeal irritation and cough (7) .
No nicotine replacement therapy product delivers an equivalent dose of nicotine as quickly as cigarette smoking (7) . Consequently, they have a limited ability to consistently and effectively counter the addictive appeal of smoking in tobacco-dependent individuals (7) .
Evidence recommends combination use of nicotine replacement therapy products that provide both continuous and at-liberty dosing (6, 7). 
PHARMACOTHERAPY NOT CONTAINING NICOTINE
Bupropion Sustained-Release
Bupropion sustained-release is the first non-nicotine prescription drug to be Food and Drug Administration (FDA)-approved as a first-line agent for tobacco dependence (6) . Bupropion mediates its effect on the brain's reward centers through norepinephrine and dopamine reuptake inhibition, as well as through competitive inhibition on nAChRs (12) . A network meta-analysis showed that bupropion significantly increased the odds of quitting as monotherapy (odds ratio=1.82; 95% CI=1.60-2.06) and demonstrated comparable efficacy with nicotine replacement therapy (13) . There was no significant difference in abstinence based on gender or dosing bupropion at 150 mg or 300 mg (relative risk=1.08, 95% CI=0.93-1.26) (14) . Bupropion has been shown to decrease withdrawal symptoms, cigarette craving, and improve mood during smoking cessation (15) . Additionally, bupropion has benefits in limiting postcessation weight gain at the end of treatment (mean weight loss=-1.12 kg; 95% CI=-1.47 to -0.77 kg), although results beyond 6 months did not demonstrate persistence of effect (16) . Bupropion was found to be safe and effective in smoking cessation in patients with schizophrenia (17) . The "target quit date" is typically set on the eighth day of bupropion treatment when the bupropion level reaches a steady-state concentration.
Common side effects include insomnia and dry mouth (14) . Bupropion should be used with caution in patients with liver disease or renal impairment and is contraindicated in those with a history of seizure, eating disorders, or head trauma with loss of consciousness or those using medications that lower seizure threshold (6) . Bupropion was associated with a seizure rate of 1:1500 but had no excess neuropsychiatric or cardiovascular events compared with placebo across all trials (13) . 
Varenicline
Varenicline was FDA approved as a firstline agent for smoking cessation in 2007 (5). Varenicline's novel therapeutic effect is through its partial agonist activity and competitive inhibition with nicotine at the α4β2 receptor, which in turn affects central mesolimbic dopamine release. As a result, varenicline mitigates symptoms of craving, withdrawal, and the reward reinforcement mechanism of nicotine (18) . A meta-analysis concluded that varenicline was the most effective treatment, nearly tripling the odds of quitting compared with placebo (odds ratio=2.88; 95% CI=2.40-3.47) (11) . Varenicline was more effective than nicotine replacement therapy (odds ratio=1.57; 95% CI=1.29-1.91) and bupropion (odds ratio=1.59; 95% CI=1.29-1.96) but not more effective than combination nicotine replacement therapy (odds ratio=1.06; 95% CI=0.75-1.48) (13) . Efficacy regarding the combination of varenicline and nicotine replacement therapy is unclear and not currently recommended by United States Public Health Service guidelines (6) . A multicenter randomized clinical trial demonstrated that combination varenicline and bupropion increased prolonged abstinence at 12 and 26 weeks compared with varenicline alone (19) . A randomized clinical trial also demonstrated that among cigarette smokers not willing or able to quit within the next month, but willing to reduce cigarette consumption and make a quit attempt at 3 months, use of varenicline for 24 weeks compared with placebo significantly increased smoking cessation rates at the end of treatment and also at 1 year (20) . A recent multicenter randomized clinical trial showed that those who had a normal nicotine metabolite ratio had significantly higher quit rates after receiving varenicline for 11 weeks compared with those receiving a nicotine patch (21) .
Varenicline is titrated to a dose of 1 mg twice daily for 12 weeks and has been shown to reduce relapse rates in abstinent smokers when given for an additional 12 weeks (22) . The most common adverse effect associated with varenicline is mild nausea (7) . Postmarketing surveillance raised concerns regarding neuropsychiatric and cardiovascular adverse events of varenicline. This prompted the FDA to issue a black box warning in 2008 regarding risks of behavioral change and suicidal ideation. A 2013 meta-analysis demonstrated no increased risk of serious adverse events with varenicline compared with placebo (relative risk=1.06; 95% CI=0.72-1.55) (13) . Subgroup analysis additionally found no difference in risk of neuropsychiatric (relative risk=0.53; 95% CI=0.17-1.67) or cardiovascular events (relative risk=1. 26; 95% CI=0.62-2.56) between varenicline and placebo (13) . However, these results are inconclusive and are included in the most updated FDA warning on varenicline (23). The FDA also changed the labeling regarding possible risk of decreased tolerance to alcohol (increased drunkenness, unusual behavior or memory loss) and rare risk of seizures within the first month of starting varenicline in patients who had either no history of seizures or had a seizure disorder that had been well controlled (23).
CONCLUSIONS
The two most effective tobacco pharmacotherapies are varenicline and combination nicotine replacement therapy, with a recent meta-analysis suggesting varenicline plus combination nicotine replacement therapy being superior to varenicline alone (24) . Additional research is underway to determine novel targets, effective pharmacotherapy combinations, optimal duration, relapse prevention strategies, and genetic determinants that improve pharmacotherapeutic efficacy (21). Mecamylamine Ganglionic blocker and noncompetitive antagonist of α4β2 nAChRs Nicotine patch in combination with transdermal mecamylamine patch or placebo did not demonstrate statically significant improvement in abstinence.
a For further details, see Elrashidi and Ebbert (25) .
KEY POINTS/CLINICAL PEARLS
• People with mental illness are more likely to use tobacco and therefore more likely to suffer from tobacco-related illness and death compared with people without prior history of mental illness.
• Tobacco dependence is due to complex and insidious effects of nicotine through nicotinic acetylcholinergic receptors on physiologic processes and neural reward pathways in the brain leading to long-term habituation.
• Pharmacotherapies are effective treatments for tobacco dependence and are recommended by the United States Public Health Service to be provided in conjunction with behavioral therapy.
• All Food and Drug Administration-approved pharmacotherapies have demonstrated benefits in promoting abstinence, but relapse rates remain high.
